Background Background Few controlled studies
Few controlled studies have examined the use of atypical have examined the use of atypical antipsychotic drugs for prevention of antipsychotic drugs for prevention of relapse in patients with bipolar I disorder. relapse in patients with bipolar I disorder.
Aims Aims To evaluate whether olanzapine
To evaluate whether olanzapine plus either lithium or valproate reduces plus either lithium or valproate reduces the rate of relapse, compared with lithium the rate of relapse, compared with lithium or valproate alone. or valproate alone.
Method Method Patients achieving syndromic
Patients achieving syndromic remission after 6 weeks'treatment with remission after 6 weeks'treatment with olanzapine plus either lithium (0.6ôlanzapine plus either lithium (0.61 .2 mmol/l) or valproate (50^125 1.2 mmol/l) or valproate (50^125 m mg/ml) g/ml)
received lithium or valproate plus either received lithium or valproate plus either olanzapine 5^20 mg/day (combination olanzapine 5^20 mg/day (combination therapy) or placebo (monotherapy), and therapy) or placebo (monotherapy), and were followed in a double-masked trial for were followed in a double-masked trial for 18 months. 18 months.
Results

The treatment difference in The treatment difference in time to relapse into either mania or time to relapse into either mania or depression was not significant for depression was not significant for syndromic relapse (median time to syndromic relapse (median time to relapse: combination therapy 94 days, relapse: combination therapy 94 days, monotherapy 40.5 days; monotherapy 40.5 days; P P¼0.742), but 0.742), but was significant for symptomatic relapse was significant for symptomatic relapse (combination therapy163 days, (combination therapy163 days, monotherapy 42 days; monotherapy 42 days; P P¼0.023). 0.023).
Conclusions Conclusions Patients taking
Patients taking olanzapine added to lithium or valproate olanzapine added to lithium or valproate experienced sustained symptomatic experienced sustained symptomatic remission, but not syndromic remission, remission, but not syndromic remission, for longer than those receiving lithium or for longer than those receiving lithium or valproate monotherapy. valproate monotherapy.
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Long-term efficacy has not been well Long-term efficacy has not been well demonstrated for most currently available demonstrated for most currently available treatment regimens for bipolar disorder. treatment regimens for bipolar disorder. Pharmacotherapy increasingly has involved Pharmacotherapy increasingly has involved combination therapy, typically consisting combination therapy, typically consisting of a combination of lithium and another of a combination of lithium and another psychotropic agent such as an antipsychotropic agent such as an antipsychotic. Historically, the use of convenpsychotic. Historically, the use of conventional antipsychotics has been hampered tional antipsychotics has been hampered by a risk of tardive dyskinesia (Kane & by a risk of tardive dyskinesia (Kane & Smith, 1982) and worsening of depression Smith, 1982) and worsening of depression (Morgan, 1972) . Atypical antipsychotics (Morgan, 1972) . Atypical antipsychotics may hold promise in avoiding the drawmay hold promise in avoiding the drawbacks of the conventional antipsychotics, backs of the conventional antipsychotics, but there have been hardly any controlled but there have been hardly any controlled studies of atypical antipsychotics in the studies of atypical antipsychotics in the prophylactic treatment of bipolar disorder. prophylactic treatment of bipolar disorder. We report here the results of an 18-month, We report here the results of an 18-month, double-masked, relapse prevention study of double-masked, relapse prevention study of patients with bipolar disorder who had patients with bipolar disorder who had achieved remission with olanzapine in comachieved remission with olanzapine in combination with lithium or valproate. This bination with lithium or valproate. This phase of the study was designed to compare phase of the study was designed to compare continuation of combination treatment continuation of combination treatment v.
v. monotherapy, using an analysis defined monotherapy, using an analysis defined a priori a priori involving both syndromic and involving both syndromic and symptomatic definitions of relapse. symptomatic definitions of relapse.
METHOD METHOD
Participants were men and women aged Participants were men and women aged 18-70 years who had achieved syndromic 18-70 years who had achieved syndromic remission from an index manic or mixed remission from an index manic or mixed episode after receiving olanzapine plus episode after receiving olanzapine plus lithium or valproate during a 6-week, lithium or valproate during a 6-week, double-masked study that compared double-masked study that compared combination treatment with lithium or combination treatment with lithium or valproate monotherapy, as previously valproate monotherapy, as previously reported (Tohen reported (Tohen et al et al, 2002) . Briefly, , 2002) . Briefly, patients received open-label lithium or patients received open-label lithium or valproate plus additional olanzapine or valproate plus additional olanzapine or placebo under double-masked conditions. placebo under double-masked conditions. All patients had been diagnosed with All patients had been diagnosed with bipolar I disorder, manic or mixed episode, bipolar I disorder, manic or mixed episode, with or without psychotic features, using with or without psychotic features, using the Structured Clinical Interview for the the Structured Clinical Interview for the DSM-IV (First DSM-IV (First et al et al, 1997; American , 1997; American Psychiatric Association, 1994) . Prior to Psychiatric Association, 1994) . Prior to enrolment in the acute phase, participants enrolment in the acute phase, participants had to have experienced at least two prehad to have experienced at least two previous mood episodes (depressed, manic or vious mood episodes (depressed, manic or mixed). They were also required to have mixed). They were also required to have had a documented trial at a therapeutic had a documented trial at a therapeutic blood level of lithium (0.6-1.2 mmol/l) or blood level of lithium (0.6-1.2 mmol/l) or valproate (50-125 valproate (50-125 m mg/ml) for at least 2 g/ml) for at least 2 weeks immediately prior to enrolment and weeks immediately prior to enrolment and to have demonstrated persistent manic to have demonstrated persistent manic symptoms, as defined from a Young Mania symptoms, as defined from a Young Mania Rating Scale (YMRS; Young Rating Scale (YMRS; Young et al et al, 1978) , 1978) total score of 16 or more at both enrolment total score of 16 or more at both enrolment (visit 1) and randomisation (visit 2). Any of (visit 1) and randomisation (visit 2). Any of the following was considered grounds for the following was considered grounds for exclusion from entry: pregnancy; serious exclusion from entry: pregnancy; serious and unstable medical illness; DSM-IV suband unstable medical illness; DSM-IV substance dependence within the past 30 days stance dependence within the past 30 days (except nicotine or caffeine); documented (except nicotine or caffeine); documented history of intolerance to olanzapine; and history of intolerance to olanzapine; and serious suicidal risk. Patients who achieved serious suicidal risk. Patients who achieved remission with the combination therapy of remission with the combination therapy of olanzapine plus lithium or valproate were olanzapine plus lithium or valproate were randomly reassigned using a unique drug randomly reassigned using a unique drug kit number (via a call-in interactive voice kit number (via a call-in interactive voice response system) in a 1:1 ratio to treatment response system) in a 1:1 ratio to treatment with either the combination of olanzapine with either the combination of olanzapine plus lithium or valproate (A) or lithium or plus lithium or valproate (A) or lithium or valproate monotherapy (B). All patients, valproate monotherapy (B). All patients, study site personnel and sponsor investigastudy site personnel and sponsor investigators were masked to the randomisation tors were masked to the randomisation codes. Prior to participation, all patients codes. Prior to participation, all patients received a complete description of the study received a complete description of the study and signed an informed consent document and signed an informed consent document approved by their study site's institutional approved by their study site's institutional review board. To enter the relapse prevenreview board. To enter the relapse prevention phase of the study, patients receiving tion phase of the study, patients receiving co-therapy during the acute phase had to co-therapy during the acute phase had to demonstrate syndromic remission accorddemonstrate syndromic remission according to established research definitions ing to established research definitions (Tohen (Tohen et al et al, 1992; Strakowski , 1992; Strakowski et al et al, , 1998) at the end of the acute phase (week 1998) at the end of the acute phase (week 6), as follows: 6), as follows:
(a) (a) DSM-IV 'A' criteria for current manic DSM-IV 'A' criteria for current manic episode no worse than mild (score episode no worse than mild (score 4 43 3 in a range of 1 to 7), 'B' criteria no in a range of 1 to 7), 'B' criteria no worse than mild ( worse than mild (4 43, range 1-7), and 3, range 1-7), and no more than two 'B' criteria that no more than two 'B' criteria that were mild (3, range 1-7); were mild (3, range 1-7); (b) (b) all DSM-IV 'A' criteria for current all DSM-IV 'A' criteria for current major depressive episode no worse major depressive episode no worse than mild ( than mild (4 43, range 1-7), and no 3, range 1-7), and no more than three 'A' criteria mild (3, more than three 'A' criteria mild (3, range 1-7). range 1-7).
Patients who received combination Patients who received combination treatment during the acute phase and had treatment during the acute phase and had achieved syndromic remission of both achieved syndromic remission of both mania and depression as defined above mania and depression as defined above were randomly reassigned at visit 8 (week were randomly reassigned at visit 8 (week 6 of the acute phase) in a 1:1 ratio to 6 of the acute phase) in a 1:1 ratio to receive an additional 18 months of doublereceive an additional 18 months of doublemasked therapy, consisting of either masked therapy, consisting of either olanzapine (flexible dosage range of 5 mg, olanzapine (flexible dosage range of 5 mg, 10 mg, 15 mg or 20 mg per day) in combi-10 mg, 15 mg or 20 mg per day) in combination with lithium or valproate (combinanation with lithium or valproate (combination therapy), or placebo added to lithium tion therapy), or placebo added to lithium or valproate (monotherapy). Patients conor valproate (monotherapy). Patients continued taking the same mood stabiliser that tinued taking the same mood stabiliser that they had received during the acute phase, they had received during the acute phase, the choice of which was determined by the choice of which was determined by the site investigator. As in the acute phase, the site investigator. As in the acute phase, mood stabiliser therapy was not masked; mood stabiliser therapy was not masked; only the addition of olanzapine or placebo only the addition of olanzapine or placebo was conducted under double-masked conwas conducted under double-masked conditions. Patients in the combination therapy ditions. Patients in the combination therapy group began treatment with 10 mg per day group began treatment with 10 mg per day of olanzapine, given on the evening of visit of olanzapine, given on the evening of visit 8. The period between visits was 1 week for 8. The period between visits was 1 week for the first two assessments (visits 9 and 10), 2 the first two assessments (visits 9 and 10), 2 weeks for the next assessment (visit 11), 4 weeks for the next assessment (visit 11), 4 weeks for the assessment after that (visit weeks for the assessment after that (visit 12), and 8 weeks for the remainder of the 12), and 8 weeks for the remainder of the study (visits 13 to 20). To maintain maskstudy (visits 13 to 20). To maintain masking, treatment took the form of two 5 mg ing, treatment took the form of two 5 mg capsules (either olanzapine or placebo), capsules (either olanzapine or placebo), titrated up in increments of one capsule, titrated up in increments of one capsule, or down by any number of decrements at or down by any number of decrements at the investigator's discretion, as indicated the investigator's discretion, as indicated by each patient's symptom improvement by each patient's symptom improvement and treatment tolerance. Patients unable and treatment tolerance. Patients unable to tolerate the minimum dose (one capsule) to tolerate the minimum dose (one capsule) were withdrawn from the study. During were withdrawn from the study. During this relapse prevention phase of the study, this relapse prevention phase of the study, the blood levels of lithium and valproate the blood levels of lithium and valproate remained within the therapeutic range remained within the therapeutic range (lithium 0.6-1.2 mmol/l, valproate 50-(lithium 0.6-1.2 mmol/l, valproate 50-125 125 m mg/ml), as previously defined. If lithium g/ml), as previously defined. If lithium or valproate levels deviated from this theraor valproate levels deviated from this therapeutic range, the investigator adjusted the peutic range, the investigator adjusted the dosage of either drug to re-establish blood dosage of either drug to re-establish blood levels within the range. Patients were perlevels within the range. Patients were permitted adjunctive use of benzodiazepines mitted adjunctive use of benzodiazepines ( (4 42 mg lorazepam equivalent per day) for 2 mg lorazepam equivalent per day) for no more than 5 consecutive days, or 60 no more than 5 consecutive days, or 60 days cumulatively. Anticholinergic therapy days cumulatively. Anticholinergic therapy (benzatropine mesylate (benzatropine mesylate 4 42 mg per day) 2 mg per day) was permitted throughout the study for was permitted throughout the study for treatment of extrapyramidal side-effects treatment of extrapyramidal side-effects but not for prophylaxis. Aside from study but not for prophylaxis. Aside from study drugs, benzodiazepines and anticholinerdrugs, benzodiazepines and anticholinergics, no other psychiatric drug was gics, no other psychiatric drug was permitted during the study. permitted during the study.
Assessments Assessments
Relapse was assessed as: Relapse was assessed as:
(a) (a) syndromic, meeting DSM-IV criteria syndromic, meeting DSM-IV criteria for a manic, mixed or depressive for a manic, mixed or depressive Patients who not only met the requirePatients who not only met the requirements for syndromic remission at the end ments for syndromic remission at the end of the acute phase but also met the symptoof the acute phase but also met the symptomatic remission criteria (YMRS total score matic remission criteria (YMRS total score 4 412 and HRSD-21 total score 12 and HRSD-21 total score 4 48) were 8) were assessed for symptomatic relapse during assessed for symptomatic relapse during this extension phase. Symptomatic relapse this extension phase. Symptomatic relapse of mania was defined as a YMRS total of mania was defined as a YMRS total score rating of 15 or greater after having score rating of 15 or greater after having previously met the criteria for symptomatic previously met the criteria for symptomatic and syndromic remission. Symptomatic and syndromic remission. Symptomatic relapse of depression was defined as an relapse of depression was defined as an HRSD-21 total score rating of 15 or greater HRSD-21 total score rating of 15 or greater after having previously met the criteria for after having previously met the criteria for both symptomatic and syndromic remission. both symptomatic and syndromic remission.
To assess relapse prevention, survival To assess relapse prevention, survival analyses were conducted to determine the analyses were conducted to determine the times to syndromic relapse (the study's pritimes to syndromic relapse (the study's primary outcome measure) and symptomatic mary outcome measure) and symptomatic relapse of any mood episode, whether relapse of any mood episode, whether manic, depressive or mixed. Times to remanic, depressive or mixed. Times to relapse were based on the date of the assesslapse were based on the date of the assessment when relapse criteria were first met ment when relapse criteria were first met or, if censored to relapse, the final assessor, if censored to relapse, the final assessment date, each relative to the date of ment date, each relative to the date of randomisation. Patient assessments were randomisation. Patient assessments were conducted by mental health care profesconducted by mental health care professionals, including psychiatrists, psychosionals, including psychiatrists, psychologists, nurses and other mental health logists, nurses and other mental health caregivers with an advanced clinical degree caregivers with an advanced clinical degree or certification. Raters were trained in the or certification. Raters were trained in the use of symptom rating scales before the use of symptom rating scales before the study began. Changes in dosage levels of study began. Changes in dosage levels of randomised therapy were made by the prerandomised therapy were made by the prescribing principal investigator at each site. scribing principal investigator at each site. This investigator might have also been This investigator might have also been responsible for outcomes assessment, but responsible for outcomes assessment, but was not necessarily the rater. was not necessarily the rater.
Serum concentrations of lithium or Serum concentrations of lithium or valproate were assessed at every visit to valproate were assessed at every visit to determine if the therapeutic blood level determine if the therapeutic blood level was maintained. To estimate the mean was maintained. To estimate the mean blood level, the area under the serum conblood level, the area under the serum concentration curve (AUC) was determined centration curve (AUC) was determined for each patient. The AUC was calculated for each patient. The AUC was calculated with a weighted average of mean serum with a weighted average of mean serum concentrations at each pair of consecutive concentrations at each pair of consecutive visits, weighted by the number of days visits, weighted by the number of days between those two visits. between those two visits.
Scales for assessment of extrapyramidal Scales for assessment of extrapyramidal side-effects included the Simpson-Angus side-effects included the Simpson-Angus Scale (Simpson & Angus, 1970) , the Barnes Scale (Simpson & Angus, 1970) , the Barnes Akathisia Rating Scale (BARS; Barnes, Akathisia Rating Scale (BARS; Barnes, 1989 ) and the Abnormal Involuntary 1989) and the Abnormal Involuntary Movement Scale (AIMS; Guy, 1976). Movement Scale (AIMS; Guy, 1976). Treatment-emergent parkinsonism was Treatment-emergent parkinsonism was defined as a Simpson-Angus Scale score defined as a Simpson-Angus Scale score greater than 3 at any time following a score greater than 3 at any time following a score of 3 or less during the acute period. Treatof 3 or less during the acute period. Treatment-emergent akathisia was defined as a ment-emergent akathisia was defined as a BARS score of 2 or more at any time fol-BARS score of 2 or more at any time following a score of less than 2 during the lowing a score of less than 2 during the acute period. A score of 3 or more on any acute period. A score of 3 or more on any of the first seven AIMS items, or a score of the first seven AIMS items, or a score of 2 or more on any two of the first seven of 2 or more on any two of the first seven AIMS items, was taken to be indicative of AIMS items, was taken to be indicative of long-term treatment-emergent dyskinetic long-term treatment-emergent dyskinetic symptoms, given that neither of these crisymptoms, given that neither of these criteria was met during the acute period. This teria was met during the acute period. This definition of treatment-emergent dyskinetic definition of treatment-emergent dyskinetic symptoms is consistent with the crosssymptoms is consistent with the crosssectional symptom severity criteria sugsectional symptom severity criteria suggested by Schooler & Kane (1982) as gested by Schooler & Kane (1982) as research diagnostic criteria. Assessment of research diagnostic criteria. Assessment of vital signs and weight and a full blood anavital signs and weight and a full blood analysis (including prolactin and non-fasting lysis (including prolactin and non-fasting glucose levels) were performed at each visit. glucose levels) were performed at each visit.
Statistical analyses Statistical analyses
The sample size was planned on the The sample size was planned on the assumption that 75% of patients receiving assumption that 75% of patients receiving olanzapine plus lithium or valproate during olanzapine plus lithium or valproate during the preceding acute phase would be in synthe preceding acute phase would be in syndromic remission, yielding approximately dromic remission, yielding approximately 168 eligible patients for the relapse pre-168 eligible patients for the relapse prevention phase of the study. With equal vention phase of the study. With equal allocation into the combination and monoallocation into the combination and monotherapy treatment groups, this sample size therapy treatment groups, this sample size provided 96% power to detect a difference provided 96% power to detect a difference in time to relapse using the log-rank test in time to relapse using the log-rank test assuming an 18-month syndromic relapse assuming an 18-month syndromic relapse of bipolar disorder of 30% and 60% for of bipolar disorder of 30% and 60% for combination therapy and monotherapy combination therapy and monotherapy respectively, and a 10% loss to follow-up respectively, and a 10% loss to follow-up in each group. Time-to-relapse curves for in each group. Time-to-relapse curves for the therapy groups were estimated with the therapy groups were estimated with the Kaplan-Meier technique and the curves the Kaplan-Meier technique and the curves were compared using the log-rank test. were compared using the log-rank test. Median length of follow-up to the point Median length of follow-up to the point of relapse or censoring is used to describe of relapse or censoring is used to describe time to relapse in each group. Similar time to relapse in each group. Similar analyses were performed to examine time analyses were performed to examine time to discontinuation. A Cox proportional to discontinuation. A Cox proportional hazards regression approach allowed hazards regression approach allowed examination of differential time to relapse examination of differential time to relapse comparing the therapies based on subgroup comparing the therapies based on subgroup factors (age, gender, racial origin, psychotic factors (age, gender, racial origin, psychotic features, history of cycling course, type of features, history of cycling course, type of index episode) by inclusion of a therapyindex episode) by inclusion of a therapysubgroup interaction. For rating scales, subgroup interaction. For rating scales, total scores were derived from the individual total scores were derived from the individual items; if any item was missing, the total items; if any item was missing, the total score was treated as missing. Analysis of score was treated as missing. Analysis of variance was used to evaluate quantitative variance was used to evaluate quantitative change, including terms for treatment, change, including terms for treatment, investigator, and treatment-investigator investigator, and treatment-investigator interaction; treatment differences are charinteraction; treatment differences are characterised with 95% confidence intervals acterised with 95% confidence intervals about the mean change difference. Fisher's about the mean change difference. Fisher's exact test was used to compare rates of exact test was used to compare rates of relapse and discontinuation; incidence rates relapse and discontinuation; incidence rates of treatment-emergent adverse events and of treatment-emergent adverse events and scale-based extrapyramidal side-effects are scale-based extrapyramidal side-effects are shown with an asymptomatic 95% confishown with an asymptomatic 95% confidence interval about the risk difference dence interval about the risk difference (combination therapy minus monotherapy).
(combination therapy minus monotherapy). Tests of treatment differences were twoTests of treatment differences were twosided, with an sided, with an a a level of 0.05; significance level of 0.05; significance of interactions was tested at an of interactions was tested at an a a level of level of 0.10. Measurements taken at the last 0.10. Measurements taken at the last acute-phase visit (end-point, week 6 of acute acute-phase visit (end-point, week 6 of acute phase) served as the baseline for all continuphase) served as the baseline for all continuous measures of efficacy and safety. Cateous measures of efficacy and safety. Categorical treatment-emergent events were gorical treatment-emergent events were defined as those that worsened or first defined as those that worsened or first occurred after the acute phase of therapy. occurred after the acute phase of therapy.
RESULTS RESULTS
Sample characteristics Sample characteristics and disposition and disposition
The study was conducted at 29 sites in the The study was conducted at 29 sites in the USA and Canada between September USA and Canada between September 1997 and October 2000. Of those assessed 1997 and October 2000. Of those assessed at the end of the preceding acute phase at the end of the preceding acute phase (Fig. 1 ), 99 patients who had received olan- (Fig. 1 ), 99 patients who had received olanzapine combined with either lithium or zapine combined with either lithium or valproate during the double-masked acute valproate during the double-masked acute phase achieved syndromic remission of phase achieved syndromic remission of bipolar disorder and were reassigned bipolar disorder and were reassigned randomly either to continue with doublerandomly either to continue with doublemasked therapy consisting of olanzapine masked therapy consisting of olanzapine in combination with lithium or valproate in combination with lithium or valproate (combination therapy, (combination therapy, n n¼51) or to 51) or to discontinue olanzapine and receive placebo discontinue olanzapine and receive placebo added to lithium or valproate (monoadded to lithium or valproate (monotherapy, therapy, n n¼48). The treatment groups were 48). The treatment groups were comparable with respect to mean age, comparable with respect to mean age, racial origin and gender (Table 1) . racial origin and gender (Table 1) .
Prior to randomisation in the acute Prior to randomisation in the acute treatment period, the median duration of treatment period, the median duration of mood stabiliser therapy immediately before mood stabiliser therapy immediately before study entry was 67 days, and 203 of the study entry was 67 days, and 203 of the 344 patients enrolled in the acute phase 344 patients enrolled in the acute phase had a duration of therapy greater than 6 had a duration of therapy greater than 6 weeks. Of the 99 patients entering the weeks. Of the 99 patients entering the relapse prevention phase, almost two-thirds relapse prevention phase, almost two-thirds ( (n n¼63) were receiving valproate. As char-63) were receiving valproate. As characterised by their index episode at study acterised by their index episode at study initiation, patients with mania ( initiation, patients with mania (n n¼50) and 50) and mixed states ( mixed states (n n¼49) were about equally 49) were about equally represented. A rapid-cycling course was represented. A rapid-cycling course was present in 41 patients, and 26 exhibited present in 41 patients, and 26 exhibited psychotic features in their index episode psychotic features in their index episode of mania. The duration and nature of the of mania. The duration and nature of the illness appear consistent between treatment illness appear consistent between treatment groups (Table 1) . groups (Table 1) .
The mean drug dosages and serum conThe mean drug dosages and serum concentrations in the two groups are shown in centrations in the two groups are shown in Table 2 . Concomitant use of benzodiaze- Table 2 . Concomitant use of benzodiazepines in the combination therapy group pines in the combination therapy group (10 of 51, 20%) was similar to that in the (10 of 51, 20%) was similar to that in the monotherapy group (14 of 48, 29%). In monotherapy group (14 of 48, 29%). In addition, concomitant use of anticholineraddition, concomitant use of anticholinergics was similar in the two groups (combigics was similar in the two groups (combination treatment 5 of 51, 10%; nation treatment 5 of 51, 10%; monotherapy 7 of 48, 15%). monotherapy 7 of 48, 15%).
The percentage of patients completing The percentage of patients completing the 18-month follow-up period was nearly the 18-month follow-up period was nearly three times higher in the combination three times higher in the combination treatment group than in the monotherapy treatment group than in the monotherapy group (combination treatment 31%, group (combination treatment 31%, monotherapy 10%; monotherapy 10%; P P¼0.014). Moreover, 0.014). Moreover, 3 3 9 3 3 9 
Relapse prevention Relapse prevention
At the start of the relapse prevention phase, At the start of the relapse prevention phase, 99 patients were assessed as being in syn-99 patients were assessed as being in syndromic remission of bipolar disorder. Time dromic remission of bipolar disorder. Time to relapse into a syndromic affective epito relapse into a syndromic affective episode, whether mania or depression, was sode, whether mania or depression, was not significantly different between the not significantly different between the treatment groups ( treatment groups (w w 2 2 1 1 ¼0.11, 0.11, P P¼0.742, 0.742, log-rank test; hazard ratio 1.13, 95% CI log-rank test; hazard ratio 1.13, 95% CI 0.55-2.31), with median times to relapse 0.55-2.31), with median times to relapse occurring at 40.5 days for the monotherapy occurring at 40.5 days for the monotherapy group and 94 days for the combination group and 94 days for the combination therapy group. Rates of syndromic relapse therapy group. Rates of syndromic relapse into either mania or depression were also into either mania or depression were also not significantly different between treatnot significantly different between treatment groups: combination therapy 15 of ment groups: combination therapy 15 of 51 (29%), monotherapy 15 of 48 (31%); 51 (29%), monotherapy 15 of 48 (31%); P P4 40.99. 0.99.
Of the 99 patients in syndromic remisOf the 99 patients in syndromic remission at entry to the relapse prevention sion at entry to the relapse prevention phase, 68 were assessed to be free from phase, 68 were assessed to be free from either manic or depressive symptoms (specieither manic or depressive symptoms (specified fied a priori a priori as YMRS score as YMRS score 4 412 and 12 and HRSD-21 score HRSD-21 score 4 48) at randomisation. 8) at randomisation. During the maintenance phase, time to During the maintenance phase, time to symptomatic relapse into either mania or symptomatic relapse into either mania or depression was significantly longer for the depression was significantly longer for the combination therapy group compared combination therapy group compared with the monotherapy group ( with the monotherapy group (w w 2 2 1 1 ¼5.19, 5.19, P P¼0.023, log-rank test, hazard ratio 2.29, 0.023, log-rank test, hazard ratio 2.29, 95% CI 1.10-4.78), with median times to 95% CI 1.10-4.78), with median times to relapse of 163 days for combination treatrelapse of 163 days for combination treatment and 42 days for monotherapy ment and 42 days for monotherapy (Fig. 2) . Rates of symptomatic relapse into (Fig. 2) . Rates of symptomatic relapse into either mania or depression were not signifeither mania or depression were not significantly different between the treatment icantly different between the treatment groups: combination therapy 11 of 30 groups: combination therapy 11 of 30 (37%); monotherapy 21 of 38 (55%); (37%); monotherapy 21 of 38 (55%); P P¼0.149. 0.149.
Time to symptomatic relapse into Time to symptomatic relapse into mania alone during the prevention phase mania alone during the prevention phase following both syndromic and symptomatic following both syndromic and symptomatic remission of both mania and depression remission of both mania and depression was longer for the combination therapy was longer for the combination therapy group, but not significantly so ( group, but not significantly so (w w 2 2 1 1 ¼2.27, 2.27, P P¼0.132, log-rank test; hazard ratio 2.12, 0.132, log-rank test; hazard ratio 2.12, 95% CI 0.78-5.77), with median times to 95% CI 0.78-5.77), with median times to relapse of 171.5 days for combination relapse of 171.5 days for combination therapy therapy v.
v. 59 days for monotherapy. Rates 59 days for monotherapy. Rates of symptomatic relapse into mania only of symptomatic relapse into mania only were also lower in the combination therapy were also lower in the combination therapy group (6 of 30, or 20%) than in the monogroup (6 of 30, or 20%) than in the monotherapy group (11 of 38, or 29%), but not therapy group (11 of 38, or 29%), but not significantly so ( significantly so (P P¼0.574). Median times 0.574). Median times to symptomatic relapse into depression to symptomatic relapse into depression alone during the extension phase (combinaalone during the extension phase (combination therapy 163 days, monotherapy 55 tion therapy 163 days, monotherapy 55 days) were not statistically significantly days) were not statistically significantly different between treatment groups different between treatment groups ( (w w 2 2 1 1 ¼3.27, 3.27, P P¼0.071, log-rank test; hazard 0.071, log-rank test; hazard ratio 2.24, 95% CI 0.91-5.50). Likewise, ratio 2.24, 95% CI 0.91-5.50). Likewise, rates of relapse into depression alone, rates of relapse into depression alone, although lower in the combination therapy although lower in the combination therapy group (7 of 30, or 23%) than in the monogroup (7 of 30, or 23%) than in the monotherapy group (15 of 38, or 40%), were not therapy group (15 of 38, or 40%), were not significantly different ( significantly different (P P¼0.197) . 0.197).
Subgroup analyses Subgroup analyses
Stratification of data regarding time to Stratification of data regarding time to relapse into either symptomatic mania or relapse into either symptomatic mania or depression was conducted using the patient depression was conducted using the patient characteristics of age, gender, racial origin, characteristics of age, gender, racial origin, presence of psychotic features, type of presence of psychotic features, type of index manic episode, presence of rapidindex manic episode, presence of rapidcycling course, and mood stabiliser used. cycling course, and mood stabiliser used. Differences in treatment responsiveness Differences in treatment responsiveness were noted between patients stratified by were noted between patients stratified by gender or racial origin (Table 3) . Reflecting gender or racial origin (Table 3) . Reflecting the overall group results, women receiving the overall group results, women receiving combination therapy were found to have combination therapy were found to have significantly longer times to a symptomatic significantly longer times to a symptomatic affective (mania or depression) relapse than affective (mania or depression) relapse than did women receiving monotherapy (Fig. 3) : did women receiving monotherapy (Fig. 3) : median time to relapse for combination median time to relapse for combination therapy 177 days therapy 177 days v.
v. monotherapy 27.5 monotherapy 27.5 days; days; P P¼0.001, log-rank test. However, 0.001, log-rank test. However, men (Fig. 4) showed no such treatment men (Fig. 4) showed no such treatment difference (median time to relapse for comdifference (median time to relapse for combination therapy 84 days bination therapy 84 days v.
v. monotherapy monotherapy 67 days; 67 days; P P¼0.811, log-rank test). Similarly, 0.811, log-rank test). Similarly, stratifying the group by racial origin stratifying the group by racial origin revealed possible differences in treatment revealed possible differences in treatment responsiveness, with White patients showresponsiveness, with White patients showing significantly longer times to symptoing significantly longer times to symptomatic relapse with combination therapy matic relapse with combination therapy than with monotherapy, whereas nonthan with monotherapy, whereas nonWhite patients showed no significant White patients showed no significant difference in treatment responsiveness. 
Safety measures Safety measures
Incidences of common treatment-emergent Incidences of common treatment-emergent adverse events (Table 4) were for the most adverse events (Table 4) were for the most part not dissimilar in the two treatment part not dissimilar in the two treatment 3 4 0 3 4 0 groups, with the exception of insomnia, groups, with the exception of insomnia, which occurred in more than a quarter which occurred in more than a quarter ( (n n¼13) of monotherapy patients compared 13) of monotherapy patients compared with only 2 (4%) combination treatment with only 2 (4%) combination treatment patients, and weight gain, which was more patients, and weight gain, which was more common with combination therapy than common with combination therapy than monotherapy (combination therapy 20%, monotherapy (combination therapy 20%, monotherapy 6%). monotherapy 6%).
On measures of extrapyramidal sideOn measures of extrapyramidal sideeffects, mean within-group changes and effects, mean within-group changes and treatment differences in changes on the treatment differences in changes on the AIMS and the Simpson-Angus and Barnes AIMS and the Simpson-Angus and Barnes scales were generally small and not scales were generally small and not clinically meaningful (Table 5) . Incidence clinically meaningful (Table 5) . Incidence rates of scale-based treatment-emergent rates of scale-based treatment-emergent parkinsonism (combination treatment parkinsonism (combination treatment 6.4%, monotherapy 8.9%; risk difference 6.4%, monotherapy 8.9%; risk difference 7 72.5%, 95% CI 2.5%, 95% CI 7 713.4 to 8.4), akathisia 13.4 to 8.4), akathisia (combination therapy 7.5%, monotherapy (combination therapy 7.5%, monotherapy 5.9%; risk difference 1.6%, 95% CI 5.9%; risk difference 1.6%, 95% CI 7 79.7 9.7 to 13.0) and dyskinesia (combination treatto 13.0) and dyskinesia (combination treatment 0%, monotherapy 4.2%; risk differment 0%, monotherapy 4.2%; risk difference ence 7 74.2%, 95% CI 4.2%, 95% CI 7 79.8 to 1.5) also 9.8 to 1.5) also did not differ in a clinically meaningful did not differ in a clinically meaningful manner. manner.
There was no common or clinically There was no common or clinically relevant treatment-related difference in relevant treatment-related difference in vital signs or electrocardiographic measure, vital signs or electrocardiographic measure, including orthostasis and corrected QT including orthostasis and corrected QT interval. Mean change in body weight from interval. Mean change in body weight from baseline to end-point was 3.8 kg greater for baseline to end-point was 3.8 kg greater for combination therapy than for monotherapy combination therapy than for monotherapy (Table 5) , and the clinically relevant (Table 5) , and the clinically relevant increase in weight ( increase in weight (5 57% change from 7% change from baseline) was greater for patients receiving baseline) was greater for patients receiving combination therapy: combination therapy combination therapy: combination therapy 27%, monotherapy 6%; risk difference 27%, monotherapy 6%; risk difference 21.2% (95% CI 7.2 to 35.2). In terms of 21.2% (95% CI 7.2 to 35.2). In terms of laboratory measures (Table 5) , patients laboratory measures (Table 5) , patients in the monotherapy group showed an in the monotherapy group showed an elevation of mean corpuscular haemoglobin elevation of mean corpuscular haemoglobin and platelet count values that was greater and platelet count values that was greater than that seen among patients in the combithan that seen among patients in the combination therapy group. Mean baseline to nation therapy group. Mean baseline to end-point changes in non-fasting glucose end-point changes in non-fasting glucose and non-fasting cholesterol levels were and non-fasting cholesterol levels were small, and there was no case of clinically small, and there was no case of clinically relevant increase in non-fasting glucose relevant increase in non-fasting glucose concentration ( concentration (5 511.1 mmol/l at any post-11.1 mmol/l at any postbaseline assessment if less than 11.1 mmol/l baseline assessment if less than 11.1 mmol/l at baseline) or in non-fasting cholesterol at baseline) or in non-fasting cholesterol concentration ( concentration (5 56.20 mmol/l at any post-6.20 mmol/l at any postbaseline assessment if less than 5.17 mmol/l baseline assessment if less than 5.17 mmol/l at baseline) in either therapy group. at baseline) in either therapy group.
DISCUSSION DISCUSSION
To our knowledge, this is the first published To our knowledge, this is the first published report of a randomised, double-masked report of a randomised, double-masked 3 4 1 3 4 1 , 2001 ). The results of this study suggest that, in patients who achieved suggest that, in patients who achieved remission from a manic or mixed episode remission from a manic or mixed episode after addition of an atypical antipsychotic after addition of an atypical antipsychotic agent such as olanzapine to previous treatagent such as olanzapine to previous treatment with lithium or valproate, the contiment with lithium or valproate, the continuation of combination treatment reduced nuation of combination treatment reduced the rate of relapse of symptomatic bipolar the rate of relapse of symptomatic bipolar episodes, compared with patients who episodes, compared with patients who stopped taking olanzapine and who stopped taking olanzapine and who continued on lithium or valproate monocontinued on lithium or valproate monotherapy. The observed difference in therapy. The observed difference in outcomes based on symptomatic or outcomes based on symptomatic or syndromic criteria may be related to the syndromic criteria may be related to the relatively more conservative definition of relatively more conservative definition of symptomatic remission used in our study. symptomatic remission used in our study. To achieve symptomatic remission, patients To achieve symptomatic remission, patients needed to achieve syndromic remission and needed to achieve syndromic remission and attain a minimum score on the YMRS and attain a minimum score on the YMRS and HRSD-21. It is possible that the more con-HRSD-21. It is possible that the more conservative definition captured patients who servative definition captured patients who were symptomatically more stable. In these were symptomatically more stable. In these patients, combination treatment was signifpatients, combination treatment was significantly more effective than monotherapy, icantly more effective than monotherapy, with the median time to relapse increasing with the median time to relapse increasing from 42 days to approximately 5 months. from 42 days to approximately 5 months. Investigators have underscored the importInvestigators have underscored the importance of assessing sub-syndromal depressive ance of assessing sub-syndromal depressive and manic symptoms (Judd and manic symptoms (Judd et al et al, 2002) . , 2002). Sub-syndromal symptoms may in fact be Sub-syndromal symptoms may in fact be the most common expression of bipolar I the most common expression of bipolar I disorder over its long-term course, and are disorder over its long-term course, and are seen at a rate three times that of syndromal seen at a rate three times that of syndromal symptoms (Judd symptoms (Judd et al et al, 2002) . Thus, when , 2002) . Thus, when presence or absence of a syndromic relapse presence or absence of a syndromic relapse is assessed, worsening of residual symptoms is assessed, worsening of residual symptoms may not be detected, and a true difference may not be detected, and a true difference between treatments may thereby be missed. between treatments may thereby be missed.
An interesting finding of this study was An interesting finding of this study was that women were more likely to relapse that women were more likely to relapse sooner with monotherapy than with combisooner with monotherapy than with combination therapy; this differential treatment nation therapy; this differential treatment response was not observed for men; nor response was not observed for men; nor did the treatment-gender interaction occur did the treatment-gender interaction occur during the acute phase of this trial. There during the acute phase of this trial. There is some published evidence of gender differis some published evidence of gender differences in treatment response (Tohen ences in treatment response (Tohen et al et al, , 2003) , and with respect to olanzapine, 2003), and with respect to olanzapine, women patients with a first-episode women patients with a first-episode psychosis appear to have a greater psychosis appear to have a greater response to olanzapine than to haloperiresponse to olanzapine than to haloperidol -an outcome not found with male dol -an outcome not found with male patients (Goldstein patients (Goldstein et al et al, 2002) . , 2002).
Tolerability Tolerability
Both the lithium and valproate monoBoth the lithium and valproate monotherapies and the combined treatment with therapies and the combined treatment with olanzapine were generally well tolerated. olanzapine were generally well tolerated. During the 18-month study, patients receivDuring the 18-month study, patients receiving combination therapy gained 2.0 kg, ing combination therapy gained 2.0 kg, compared with a loss of 1.8 kg in the monocompared with a loss of 1.8 kg in the monotherapy group. It should be noted, however, therapy group. It should be noted, however, that patients had already gained an average that patients had already gained an average of 3.1 kg during the 6-week acute phase of 3.1 kg during the 6-week acute phase (Tohen (Tohen et al et al, 2002) . The loss of weight in , 2002). The loss of weight in the monotherapy patients was probably the monotherapy patients was probably secondary to the discontinuation of olanzasecondary to the discontinuation of olanzapine. Thus, the weight gain of 2.0 kg in the pine. Thus, the weight gain of 2.0 kg in the relapse prevention phase should be considrelapse prevention phase should be considered additional weight gain after a longer ered additional weight gain after a longer exposure to olanzapine. These mean longexposure to olanzapine. These mean longterm weight increases of 5-6 kg with the term weight increases of 5-6 kg with the use of olanzapine in combination with use of olanzapine in combination with lithium or valproate are similar to those lithium or valproate are similar to those reported during long-term monotherapy of reported during long-term monotherapy of bipolar disorder (Bowden bipolar disorder (Bowden et al et al, 2003) and , 2003) and in schizophrenia (Kinon in schizophrenia (Kinon et al et al, 2001) . , 2001).
3 4 2 3 4 2 valproate ( valproate (n n¼14; solid line) had a significantly longer 14; solid line) had a significantly longer time to relapse ( time to relapse (P P¼0.001, log-rank test) than women 0.001, log-rank test) than women receiving lithium or valproate plus placebo ( receiving lithium or valproate plus placebo (n n¼20; 20; dotted line); median time to relapse was177 days for dotted line); median time to relapse was177 days for combination therapy and 27.5 days for monotherapy. combination therapy and 27.5 days for monotherapy. .5 ( 8.5 (7 717.9 to 1.0) 17.9 to 1.0)
1. Common (incidence 1. Common (incidence 5 510%) treatment-emergent adverse events in either group. 10%) treatment-emergent adverse events in either group. 2. Treatment difference in incidence of treatment-emergent adverse events, olanzapine combination therapy minus 2. Treatment difference in incidence of treatment-emergent adverse events, olanzapine combination therapy minus monotherapy; asymptomatic 95% confidence interval about the difference. monotherapy; asymptomatic 95% confidence interval about the difference.
Extrapyramidal side-effects were minimal Extrapyramidal side-effects were minimal in both treatment groups. The association in both treatment groups. The association with extrapyramidal side-effects, particuwith extrapyramidal side-effects, particularly tardive dyskinesia, has long been larly tardive dyskinesia, has long been regarded as a major drawback of typical regarded as a major drawback of typical antipsychotics, as patients with bipolar disantipsychotics, as patients with bipolar disorder appear to be more susceptible to such order appear to be more susceptible to such effects than are patients with schizophrenia effects than are patients with schizophrenia (Kane & Smith, 1982) . (Kane & Smith, 1982) .
There was no abnormal increase in There was no abnormal increase in non-fasting blood glucose or cholesterol non-fasting blood glucose or cholesterol levels at any time in the study group on levels at any time in the study group on the 18-month follow-up period. This study the 18-month follow-up period. This study might not have had sufficient power to might not have had sufficient power to determine treatment differences; furtherdetermine treatment differences; furthermore, assessment of the potential impact more, assessment of the potential impact of treatment on glucose homoeostasis was of treatment on glucose homoeostasis was limited because the glucose measurements limited because the glucose measurements were non-fasting. Laboratory changes that were non-fasting. Laboratory changes that were noted included an increase in platelet were noted included an increase in platelet count with monotherapy, but not with count with monotherapy, but not with combination therapy; the significance of combination therapy; the significance of this difference, however, is not readily this difference, however, is not readily apparent. apparent.
Methodological limitations Methodological limitations
Several limitations of the current study bear Several limitations of the current study bear mentioning. First, the statistical power of mentioning. First, the statistical power of the study was based on the assumption that the study was based on the assumption that 168 patients receiving olanzapine plus 168 patients receiving olanzapine plus lithium or valproate during the preceding lithium or valproate during the preceding acute phase would have met remission acute phase would have met remission criteria; however, only 99 patients were criteria; however, only 99 patients were available for the second randomisation. available for the second randomisation. This reduced sample size provided approxiThis reduced sample size provided approximately 79% power (using assumed relapse mately 79% power (using assumed relapse rates for combination therapy and monorates for combination therapy and monotherapy as in the original estimation) and therapy as in the original estimation) and might have prevented the primary outcome might have prevented the primary outcome variable from being statistically significant. variable from being statistically significant. Second, the clinical characteristics of the Second, the clinical characteristics of the patient sample might not have been reprepatient sample might not have been representative of the general patient population sentative of the general patient population treated in clinical settings, as it contained treated in clinical settings, as it contained a high proportion of patients whose bipolar a high proportion of patients whose bipolar I disorder had had a rapid-cycling course I disorder had had a rapid-cycling course in the previous year. Patients with a rapidin the previous year. Patients with a rapidcycling course may be refractory to treatcycling course may be refractory to treatment with lithium (Bench ment with lithium (Bench et al et al, 1996); it , 1996) ; it would therefore be expected that patients would therefore be expected that patients in the monotherapy group would have a in the monotherapy group would have a particularly poor outcome owing to a weak particularly poor outcome owing to a weak response to lithium treatment, and indeed response to lithium treatment, and indeed we found that the median time to relapse we found that the median time to relapse in this group was shorter than that obin this group was shorter than that observed during prophylactic lithium treatserved during prophylactic lithium treatment in other trials (Cuesta ment in other trials (Cuesta et al et al, 2001 (Cuesta et al et al, ). , 2001 ). Related to this point is the fact that the paRelated to this point is the fact that the patients in this study represented a somewhat tients in this study represented a somewhat 'enriched' sample, inasmuch as they were 'enriched' sample, inasmuch as they were required to show incomplete responses to required to show incomplete responses to a preceding 2-week treatment with lithium a preceding 2-week treatment with lithium or valproate and then respond satisfactorily or valproate and then respond satisfactorily to concomitant treatment with olanzapine. to concomitant treatment with olanzapine. This may limit our ability to generalise This may limit our ability to generalise the results of the study to all patients. On the results of the study to all patients. On the other hand, this study is thereby one the other hand, this study is thereby one of only a few to address the question of of only a few to address the question of whether a particular treatment that prowhether a particular treatment that produces an improvement acutely -in this duces an improvement acutely -in this case, olanzapine -is able to maintain that case, olanzapine -is able to maintain that improvement; that is, whether what gets improvement; that is, whether what gets the patient well can keep the patient well. the patient well can keep the patient well. Another limitation of our study is that Another limitation of our study is that although plasma concentrations of both although plasma concentrations of both lithium and valproate were maintained well lithium and valproate were maintained well within the target range and were in line within the target range and were in line with those of other maintenance studies with those of other maintenance studies (Cuesta (Cuesta et al et al, 2001) , the valproate levels , 2001), the valproate levels were nevertheless towards the lower end were nevertheless towards the lower end of the therapeutic range. In addition, as of the therapeutic range. In addition, as was discussed in the report of the preceding was discussed in the report of the preceding study phase (Tohen study phase (Tohen et al et al, 2002 (Tohen et al et al, ), assignment , 2002 , assignment of patients to lithium or valproate was of patients to lithium or valproate was made on the basis of the treatment prefermade on the basis of the treatment preferences of the attending clinicians, rather ences of the attending clinicians, rather than through randomisation. Accordingly, than through randomisation. Accordingly, the study was not powered to show signithe study was not powered to show significant differences in outcome variables ficant differences in outcome variables 3 4 3 3 4 3 stratified by lithium or valproate treatment. stratified by lithium or valproate treatment. It was therefore not possible to determine It was therefore not possible to determine the relative efficacies and safety considerthe relative efficacies and safety consideration of these two agents during the course ation of these two agents during the course of this 18-month treatment period. Another of this 18-month treatment period. Another limitation was the small sample size in limitation was the small sample size in several of the subgroup analyses, which several of the subgroup analyses, which might have prevented detection of differenmight have prevented detection of differential treatment responses. Finally, a treattial treatment responses. Finally, a treatment group for olanzapine monotherapy ment group for olanzapine monotherapy was not included. Therefore, an assessment was not included. Therefore, an assessment of any synergistic effect between olanzapine of any synergistic effect between olanzapine plus lithium or valproate cannot be made, plus lithium or valproate cannot be made, as it would be necessary to demonstrate as it would be necessary to demonstrate that the combination treatment is more that the combination treatment is more effective than each of the monotherapies effective than each of the monotherapies alone. alone.
In summary, our results indicate that In summary, our results indicate that long-term use of the combination of olanzalong-term use of the combination of olanzapine plus lithium or valproate may prolong pine plus lithium or valproate may prolong the time spent in symptomatic remission the time spent in symptomatic remission compared with lithium or valproate monocompared with lithium or valproate monotherapy in patients who have achieved therapy in patients who have achieved remission with the combination treatment. remission with the combination treatment. The most clinically meaningful adverse The most clinically meaningful adverse event was a mean increase in body weight event was a mean increase in body weight in the combination therapy group amountin the combination therapy group amounting to a gain of 2.0 kg over the 18-month ing to a gain of 2.0 kg over the 18-month relapse prevention phase, compared with a relapse prevention phase, compared with a loss of 1.8 kg in the monotherapy group. loss of 1.8 kg in the monotherapy group. These findings may be useful to clinicians These findings may be useful to clinicians for evaluating the relative risks and benefits for evaluating the relative risks and benefits for each individual patient in determining for each individual patient in determining the selection of pharmacological treatment. the selection of pharmacological treatment. Schooler 
